Explore the science behind breakthroughs: a list of publications of our advanced cancer diagnostic platform now available

Uniogen’s cancer diagnostic platform is based on research conducted and published at the University of Turku. Studies show that the concept of glycosylation-specific immunoassays is clearly superior to currently used blood-based markers in cancer diagnosis and monitoring.

See the list of publications here: Cancer diagnostics – Uniogen

In addition, Uniogen owns several patents related to the technology and has performed inhouse research, which has led to the diagnostic product development at Uniogen.

Abacus Diagnostica, Kaivogen and Labrox are now Uniogen

Uniogen is a global pioneer in clinical diagnostics, point-of-care testing, and instrumentation for life sciences.

Uniogen – Enabling diagnosis and care at first appointment